Ki67, a proliferation marker commonly assessed by immunohistochemistry in breast cancer, holds significant value in subtype classification, prognosis, and response to therapies, with 14% of Ki67 + cells commonly accepted as a cutoff point [39]. Here, MKI67 is linked to breast cancer.